Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MediClin AGXTER:MED +1.00%75 EV-to-EBIT is 7.33 as of Aug. 22, 2026, which is 67% below its 10-year median of 22.04. GuruFocus rates XTER:MED with a GF Score™ of 75/100 and a GF Value™ of €3.20 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 474 Healthcare Providers & Services companies, MediClin AG ranks better than 83.12% on this metric.
The historical rank and industry rank for MediClin AG's EV-to-EBIT or its related term are showing as below:
XTER:MED'
s EV-to-EBIT Range Over the Past 10 Years
Min: -1487 Med: 22.04 Max: 2291.53
Current: 7.33
During the past 13 years, the highest EV-to-EBIT of MediClin AG was 2291.53. The lowest was -1487.00. And the median was 22.04.
XTER:MED's EV-to-EBIT is ranked better than 83.12% of 474
companies
in the Healthcare Providers & Services industry
Industry Median: 15.845
vs XTER:MED: 7.33
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
MediClin AG's Enterprise Value for the quarter that ended in Jun. 2026 was €397.8 Mil.
MediClin AG's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €61.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MediClin AG EV-to-EBIT Related Terms
MediClin AG EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for MediClin AG's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, MediClin AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MediClin AG EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, MediClin AG's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where MediClin AG's EV-to-EBIT falls into.
MediClin AG's current Enterprise Value is €449.6 Mil.
MediClin AG's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €61.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MediClin AG (XTER:MED) has a EV-to-EBIT of 7.33 as of Aug. 22, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on MediClin AG and its competitors. This is 67% below median its historical median of 22.04. According to the industry distribution chart, MediClin AG ranks #80 out of 474 companies in the Healthcare Providers & Services industry, placing it in the top 16.9%.
Is MediClin AG's EV-to-EBIT too high?
MediClin AG's current EV-to-EBIT of 7.33 is 67% below median its 10-year median of 22.04. The Healthcare Providers & Services industry median EV-to-EBIT is 15.85. MediClin AG's value of 7.33 is 53.7% below this industry median. Based on the distribution chart, MediClin AG ranks #80 out of 474 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, MediClin AG has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does MediClin AG's EV-to-EBIT compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, MediClin AG ranks #80 out of 474 companies for EV-to-EBIT. This places MediClin AG in the top 17% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 15.85. MediClin AG's value of 7.33 is 53.7% below this benchmark. While the company's 10-year median is 22.04 vs. the industry median of 15.85, MediClin AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 15.85, based on 474 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MediClin AG's current EV-to-EBIT of 7.33 is 53.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on MediClin AG and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 15.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MediClin AG's current EV-to-EBIT is 7.33, which is 67% below median its own 10-year median of 22.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MediClin AG stock overvalued right now?
Based on GuruFocus' analysis, MediClin AG (XTER:MED) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.20, compared to a current price of €5.05 — trading 57.8% above its estimated fair value. The current EV-to-EBIT is 7.33, which is 67% below median its 10-year median of 22.04 and 53.7% below the Healthcare Providers & Services industry median of 15.85. MediClin AG's overall GF Score™ is 75/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For MediClin AG (XTER:MED), the current EV-to-EBIT is 7.33 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MediClin AG (XTER:MED) Overvalued in 2026?
Based on GuruFocus' analysis, MediClin AG stock appears to be overvalued.
The current stock price of €5.05 is trading 57.8% above its estimated GF Value™ of €3.20.
GuruFocus considers MediClin AG to be Significantly Overvalued.
Key valuation signals for XTER:MED:
EV-to-EBIT: 7.33 (67% below median its 10-year median of 22.04)
GF Value™: €3.20 vs. price of €5.05 (57.8% above fair value)
Industry Position: 53.7% below the Healthcare Providers & Services median (#80 of 474)
No single metric tells the full story. See the XTER:MED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MediClin AG operates hospitals and other medical care centers. The company's reportable operating segments are the Post-acute, Acute, Nursing care, and Service segments. A majority of its revenue is generated from the Post-acute segment, which offers services in the fields of follow-up rehabilitation treatment and curative treatment. Some of the post-acute hospitals also offer services in acute neurology and acute psychosomatics. The Acute segment encompasses medical offerings with a focus on neurology and neurological early rehabilitation as well as psychosomatic medicine, psychiatry, orthopaedics, and internal medicine. The Nursing care segment offers full-time and part-time nursing care as well as daycare, and the Service segment consists of the central services.
75GF Score
Get the complete analysis for XTER:MED
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:MED has been successfully added to your 
